Vitaxin

Vitaxin
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	alpha-v beta-3 integrin
Clinical data
Trade names	Vitaxin
ATC code	none;
Identifiers
ChemSpider	none;
	(what is this?)

Vitaxin (MEDI-523) is a humanized monoclonal antibody against the vascular integrin alpha-v beta-3.[1] It is shown to be a promising angiogenesis inhibitor used in the treatment of some forms of cancer. Vitaxin was in 2002 being studied for rheumatoid arthritis.[2] It is the developmental precursor of Etaracizumab (MEDI-522). Both are derived from the mouse antibody LM609.[3]

Vitaxin is safe for humans. It has little effect on advanced cancer.[3]

4. [4]== References ==

F Vande Woude G, Klein G (2000). Advances in Cancer Research. Academic Press. pp. 27. ISBN 978-0-12-006679-7.
Wilder RL (November 2002). "Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases". Annals of the Rheumatic Diseases. 61 Suppl 2: ii96-9. doi:10.1136/ard.61.suppl_2.ii96. PMC 1766704. PMID 12379637.
McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, et al. (November 2005). "Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion". Clinical Cancer Research. 11 (21): 7851–60. doi:10.1158/1078-0432.CCR-05-0262. PMID 16278408.
Gramoun, Azza; Shorey, Seema; Bashutski, Jill D.; Dixon, S. Jeffrey; Sims, Stephen M.; Heersche, Johan N. M.; Manolson, Morris F. (2007). "Effects of Vitaxin®, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro". Journal of Cellular Biochemistry. 102 (2): 341–352. doi:10.1002/jcb.21296. PMID 17390341. S2CID 44708059.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] F Vande Woude G, Klein G (2000). Advances in Cancer Research. Academic Press. pp. 27. ISBN 978-0-12-006679-7.

[2] Wilder RL (November 2002). "Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases". Annals of the Rheumatic Diseases. 61 Suppl 2: ii96-9. doi:10.1136/ard.61.suppl_2.ii96. PMC 1766704. PMID 12379637.

[522trial-3] McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, et al. (November 2005). "Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion". Clinical Cancer Research. 11 (21): 7851–60. doi:10.1158/1078-0432.CCR-05-0262. PMID 16278408.

[4] Gramoun, Azza; Shorey, Seema; Bashutski, Jill D.; Dixon, S. Jeffrey; Sims, Stephen M.; Heersche, Johan N. M.; Manolson, Morris F. (2007). "Effects of Vitaxin®, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro". Journal of Cellular Biochemistry. 102 (2): 341–352. doi:10.1002/jcb.21296. PMID 17390341. S2CID 44708059.